Human CCR6 Full Length Protein (VLP)
分子别名（Synonym）
BN-1, C-C CKR-6, CC-CKR-6, CCR-6, CD196, CKR-L3, CKRL3, CMKBR6, DCR2, DRY6, GPR29, GPRCY4, STRL22
表达区间及表达系统（Source）
Human CCR6 Full Length Protein (VLP) (CC6-H52P3) is expressed from human 293 cells (HEK293).
蛋白结构（Molecular Characterization）
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
制剂（Formulation）
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.
背景（Background）
该基因编码β趋化因子受体家族的一个成员，预计它是一种类似于G蛋白偶联受体的七跨膜蛋白。该基因优先由未成熟的树突细胞和记忆T细胞表达。该受体的配体是巨噬细胞炎性蛋白3α（MIP-3α）。该受体已被证明对B谱系成熟和抗原驱动的B细胞分化很重要，它可能在炎症和免疫反应中调节树突状细胞和T细胞的迁移和募集。编码相同蛋白质的剪接转录变体已被描述用于该基因。
关键字： CCR6;CCR6蛋白;CCR6重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。